Anders Österborg

15.8k total citations
204 papers, 7.5k citations indexed

About

Anders Österborg is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Anders Österborg has authored 204 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Genetics, 112 papers in Immunology and 71 papers in Pathology and Forensic Medicine. Recurrent topics in Anders Österborg's work include Chronic Lymphocytic Leukemia Research (109 papers), Lymphoma Diagnosis and Treatment (71 papers) and Immunodeficiency and Autoimmune Disorders (44 papers). Anders Österborg is often cited by papers focused on Chronic Lymphocytic Leukemia Research (109 papers), Lymphoma Diagnosis and Treatment (71 papers) and Immunodeficiency and Autoimmune Disorders (44 papers). Anders Österborg collaborates with scholars based in Sweden, United States and Germany. Anders Österborg's co-authors include Håkan Mellstedt, Jeanette Lundin, Mahmood Jeddi‐Tehrani, Matti Aapro, Eva Kimby, Qing Yi, Marzia Palma, Lotta Hansson, Lazzaro Repetto and Hartmut Link and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Anders Österborg

202 papers receiving 7.3k citations

Peers

Countries citing papers authored by Anders Österborg

Since Specialization

Citations

This map shows the geographic impact of Anders Österborg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Österborg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Österborg more than expected).

Fields of papers citing papers by Anders Österborg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anders Österborg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Österborg. The network helps show where Anders Österborg may publish in the future.

Co-authorship network of co-authors of Anders Österborg

This figure shows the co-authorship network connecting the top 25 collaborators of Anders Österborg. A scholar is included among the top collaborators of Anders Österborg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anders Österborg. Anders Österborg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era 2025 ·Blood Advances ·Pontus Hedberg, (unknown), (unknown), (unknown), (unknown), Fredrik Kahn, Åsa Nilsdotter‐Augustinsson, Mats Fredrikson, Sofia Nyström, Peter Bergman, Christina Carlander, Soo Aleman, Pontus Nauclér, Anders Österborg, Lotta Hansson	1
2	Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia 2023 ·Journal of Hematology ·Maria Andersson, Jinghua Wu, David Wullimann, Yu Gao, Mikael Åberg, Sandra Muschiol, Katie Healy, (unknown), (unknown), Marzia Palma, Håkan Mellstedt, Puran Chen, Hans‐Gustaf Ljunggren, Lotta Hansson, Margaret Chen, Marcus Buggert, (unknown), Anders Österborg	3
3	A CX3CR1 (fractalkine receptor) Small Molecular Antagonist (KAND567) Suppressed the Growth Promoting Effect of Monocytes on Chronic Lymphocytic Leukemia Cells 2023 ·Blood ·Mohammad Hojjat‐Farsangi, (unknown), (unknown), Ann Svensson, Jeanette Lundin, Marzia Palma, Johan Schultz, Thomas Olin, Björn E. Wahlin, Anders Österborg, Parviz Kokhaei, Håkan Mellstedt	1
4	Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients 2021 ·Leukemia ·(unknown), Gordana Bogdanović, Marcus Buggert, Yu Gao, Sophia Hober, Katie Healy, Hemming Johansson, Christian Kjellander, (unknown), Sandra Muschiol, Peter Nilsson, Marzia Palma, Elisa Pin, Smith Rjh, (unknown), Margaret Chen, Rula Zain, Lotta Hansson, Anders Österborg	23
5	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials 2018 ·British Journal of Haematology ·Jeffrey A. Jones, Anthony R. Mato, Steven Coutré, John C. Byrd, Richard R. Furman, Peter Hillmen, Anders Österborg, Constantine S. Tam, Stephan Stilgenbauer, William G. Wierda, Nyla A. Heerema, Karl Eckert, Fong Clow, Cathy Zhou, Alvina D. Chu, Danelle F. James, Susan O’Brien	32
6	First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013 2018 ·Haematologica ·(unknown), (unknown), Hemming Johansson, Jenny Klintman, (unknown), (unknown), Eva Kimby, Stefan Norin, Per‐Ola Andersson, Claes Karlsson, Karin Karlsson, Birgitta Lauri, Mattias Mattsson, Anna Sandstedt, Maria Strandberg, Anders Österborg, Lotta Hansson	28
7	Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013 2017 ·Blood ·(unknown), (unknown), Hemming Johansson, Jenny Klintman, (unknown), (unknown), Eva Kimby, Stefan Norin, (unknown), Claes Karlsson, Karin Karlsson, Birgitta Lauri, Mattias Mattsson, Anna Sandstedt, Maria Strandberg, Anders Österborg, Lotta Hansson	1
8	First-in-Class Oral Small Molecule Against the Tyrosine Kinase ROR1 (KAN0439834) Induced Significant Apoptosis of Chronic Lymphocytic Leukemia Cells 2017 ·Blood ·Mohammad Hojjat‐Farsangi, Amir Hossein Daneshmanesh, Fariba Mozaffari, Lotta Hansson, (unknown), Styrbjörn Byström, Elisabeth Olsson, (unknown), (unknown), Johan Schultz, Martin Norin, Thomas Olin, Anders Österborg, Ali Moshfegh, Håkan Mellstedt	1
9	Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program 2017 ·Blood ·(unknown), Per‐Ola Andersson, (unknown), Karin Karlsson, Claes Karlsson, Birgitta Lauri, Jeanette Lundin, Mattias Mattsson, Stefan Norin, Anna Sandstedt, Lotta Hansson, Anders Österborg	2
10	First generation of a small chemical molecule ROR1 RTK tyrosine kinase inhibitor 2016 ·Annals of Oncology ·Håkan Mellstedt, Mohammad Hojjat‐Farsangi, Amir Hossein Daneshmanesh, Ali Moshfegh, (unknown), Martin Norin, Thomas Olin, Johan Schultz, (unknown), Anders Österborg	3
11	Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia 2015 ·PLoS ONE ·Mohammad Hojjat‐Farsangi, Mahmood Jeddi‐Tehrani, Amir Hossein Daneshmanesh, Fariba Mozaffari, Ali Moshfegh, Lotta Hansson, Seyed Mohsen Razavi, Ramazan Ali Sharifian, Hodjattallah Rabbani, Anders Österborg, Håkan Mellstedt, Fazel Shokri	13
12	Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis 2014 ·The Journal of Clinical Pharmacology ·Herbert Struemper, Mark Sale, Bela Patel, Mikkel Østergaard, Anders Österborg, William G. Wierda, Anton Hagenbeek, Bertrand Coiffier, Roxanne C. Jewell	22
13	Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies 2012 ·Leukemia & lymphoma ·Amir Hossein Daneshmanesh, Anna Porwit, Mohammad Hojjat‐Farsangi, Mahmood Jeddi‐Tehrani, Katja Pokrovskaja Tamm, Dan Grandér, Sören Lehmann, Stefan Norin, Fazel Shokri, Hodjattallah Rabbani, Håkan Mellstedt, Anders Österborg	63
14	Anaemia and cancer: oral or intravenous iron? 2012 ·Open Repository and Bibliography (University of Liège) ·Matti Aapro, Anders Österborg, Pere Gascón, Heinz Ludwig, Yves Béguin	1
15	Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC) 2008 ·Annals of Oncology ·(unknown), Parviz Kokhaei, Lotta Hansson, Håkan Mellstedt, Anders Österborg	11
16	Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma - evaluation of T-cell responses by different read-out systems 2007 ·Haematologica ·(unknown), Lotta Hansson, I. Eriksson, Barbro Näsman‐Glaser, (unknown), Hodjatallah Rabbani, Håkan Mellstedt, Anders Österborg	10
17	Strategies in the Management of Alemtuzumab-Related Side Effects 2006 ·Seminars in Oncology ·Anders Österborg, Claes Karlsson, Jeanette Lundin, Eva Kimby, Håkan Mellstedt	43
18	Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B‐CLL) 2002 ·European Journal Of Haematology ·Eva Rossmann, Nongnit Lewin, Mahmood Jeddi‐Tehrani, Anders Österborg, Håkan Mellstedt	45
19	Dendritic cells in patients with non‐progressive B‐chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern 2001 ·British Journal of Haematology ·(unknown), Mahmood Jeddi‐Tehrani, Peter Biberfeld, Johan Söderlund, Håkan Mellstedt, Anders Österborg, Hodjattallah Rabbani	29
20	Local low-dose of soluble GM-CSF significantly augments an immune response against tumour antigens in man 1999 ·European Journal of Cancer ·Håkan Mellstedt, Jan Fagerberg, Anders Österborg	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact